CODEN: WJAPAC Impact Factor: 5.48 ISSN: 3049-3013

World Journal of Advance Pharmaceutical Sciences

Volume 3, Issue 5, Page: 137-139 Review Article www.wjaps.com

STRATEGIC EVOLUTION OF PHARMACOVIGILANCE IN THE MODERN HEALTHCARE ECOSYSTEM: A SYSTEMATIC REVIEW AND FUTURE OUTLOOK

Devanssh Mehta*

Founder & Director, TRM Writer's LLP Founder, Market Mavericks Digital OPC Pvt Ltd Modipuram, Meerut, Uttar Pradesh, India – 250110.

How to cite this Article: Devanssh Mehta*. (2026). STRATEGIC EVOLUTION OF PHARMACOVIGILANCE IN THE MODERN HEALTHCARE ECOSYSTEM: A SYSTEMATIC REVIEW AND FUTURE OUTLOOK. World Journal of Advance Pharmaceutical Sciences, 3(5), 137-139.

Article Info

Article Received: 27 March 2026,

Article Revised: 17 April 2026,

Article Accepted: 07 May 2026.

DOI: https://doi.org/10.5281/zenodo.20098124

***Corresponding author:**

Devanssh Mehta

Founder & Director, TRM Writer's LLP Founder, Market Mavericks Digital OPC Pvt Ltd Modipuram, Meerut, Uttar Pradesh, India – 250110.

ABSTRACT

Pharmacovigilance has emerged as a critical pillar of contemporary healthcare systems, transitioning from a passive adverse drug reaction (ADR) reporting mechanism to a proactive, technology-driven discipline. This review systematically evaluates the evolution, current landscape, and future trajectory of pharmacovigilance within the global healthcare ecosystem. The increasing complexity of therapeutic interventions, including biologics, biosimilars, and personalized medicine, necessitates robust safety monitoring frameworks that extend beyond traditional pharmacovigilance methodologies. A structured literature review methodology was employed, analyzing peer-reviewed articles, regulatory reports, and global pharmacovigilance guidelines published between 2000 and 2024. The findings highlight the integration of artificial intelligence (AI), machine learning, and real-world evidence (RWE) as transformative forces enhancing signal detection, risk assessment, and regulatory decision-making. Furthermore, global harmonization efforts led by regulatory authorities such as the World Health Organization (WHO), International Council for Harmonisation (ICH), and regional agencies have significantly improved pharmacovigilance efficiency and transparency. However, persistent challenges remain, including underreporting of ADRs, data heterogeneity, regulatory disparities, and ethical concerns regarding patient data privacy. The COVID-19 pandemic further underscored the necessity for real-time pharmacovigilance systems to monitor vaccine safety and maintain public trust. This review concludes that pharmacovigilance is no longer solely a regulatory obligation but a strategic enabler of healthcare sustainability and pharmaceutical innovation. Future directions emphasize predictive pharmacovigilance models, digital integration, and patient-centric frameworks to ensure improved therapeutic safety outcomes.

KEYWORDS: Pharmacovigilance; Adverse Drug Reactions; Artificial Intelligence; Real-World Evidence; Drug Safety.

1. INTRODUCTION

Pharmacovigilance constitutes a fundamental component of modern healthcare, ensuring the safety and efficacy of medicinal products across their lifecycle. According to the World Health Organization (WHO), pharmacovigilance encompasses the science and activities related to detecting, assessing, understanding,

and preventing adverse effects or drug-related problems (WHO, 2023).

The discipline gained global prominence following the thalidomide tragedy of the 1960s, which exposed significant limitations in pre-marketing clinical trials (McBride, 1961). Since then, pharmacovigilance has evolved into a sophisticated, multi-dimensional system integrating clinical, regulatory, and technological domains.

In the current era, the proliferation of complex therapies such as biologics, gene therapies, and precision medicine has amplified the need for advanced pharmacovigilance systems. Additionally, globalization of pharmaceutical markets and increasing patient awareness have intensified regulatory scrutiny and accountability (Edwards and Aronson, 2000).

This review aims to critically analyze the evolution of pharmacovigilance, evaluate current frameworks, and explore future innovations shaping drug safety monitoring.

2. METHODOLOGY

A systematic literature review approach was adopted to ensure comprehensive coverage and academic rigor.

2.1 Data Sources

- PubMed
- Scopus
- Web of Science
- WHO and regulatory agency reports

2.2 Inclusion Criteria

Peer-reviewed articles (2000–2024)
Studies focusing on pharmacovigilance systems, technologies, and regulations
English-language publications

2.3 Exclusion Criteria

Non-peer-reviewed articles
Studies lacking methodological clarity
Duplicated data sources

2.3 Data Analysis

Thematic analysis was conducted to identify key trends, challenges, and innovations in pharmacovigilance.

3. Evolution of Pharmacovigilance

Pharmacovigilance has transitioned through distinct phases:

3.1 Reactive Phase

Initial systems relied on spontaneous ADR reporting, often limited by underreporting and lack of standardization (Hazell and Shakir, 2006).

3.2 Structured Regulatory Phase

The establishment of global monitoring systems, including WHO's Programme for International Drug Monitoring, introduced structured frameworks for data collection and analysis.

3.3 Digital and Predictive Phase

Modern pharmacovigilance incorporates AI, big data, and predictive analytics to enhance efficiency and accuracy (Aronson, 2020).

4. Core Components of Modern Pharmacovigilance

4.1 Adverse Drug Reaction Reporting

ADR reporting remains the cornerstone, supported by healthcare professionals, patients, and pharmaceutical companies.

4.2 Signal Detection

Advanced statistical models and machine learning algorithms are employed to detect safety signals (Bate and Evans, 2009).

4.3 Risk Management Systems

Risk Management Plans (RMPs) ensure continuous monitoring and mitigation of drug-related risks (EMA, 2021).

4.3 Regulatory Frameworks

Global harmonization through ICH guidelines ensures consistency in pharmacovigilance practices.

5. Technological Integration

5.1 Artificial Intelligence

AI enables automated case processing and predictive safety analysis.

5.2 Real-World Evidence

RWE provides insights into drug safety in real-world settings beyond clinical trials (Sherman et al., 2016).

5.3 Blockchain Technology

Blockchain enhances data security and transparency (Benchoufi and Ravaud, 2017).

6. Impact of COVID-19 on Pharmacovigilance

The COVID-19 pandemic accelerated pharmacovigilance innovation, particularly in vaccine safety monitoring. Real-time data analysis and global collaboration were critical in identifying adverse events and ensuring public confidence.

7. Challenges

Underreporting of ADRs
Data fragmentation
Regulatory inconsistencies
Ethical and privacy concerns
Limited awareness in developing countries

8. Pharmacovigilance in India

India's Pharmacovigilance Programme of India (PvPI) has significantly improved ADR reporting. However, challenges such as infrastructure limitations and training gaps persist (IPC, 2022).

9. Future Perspectives

9.1 Predictive Pharmacovigilance

AI-driven models will enable proactive risk identification.

9.2 Patient-Centric Systems

Increased patient involvement in ADR reporting.

9.3 Global Harmonization

Standardization of pharmacovigilance practices worldwide.

10. DISCUSSION

The transformation of pharmacovigilance reflects the increasing complexity of healthcare systems. Integration of digital technologies has enhanced efficiency but also introduced new challenges requiring multidisciplinary solutions.

11. CONCLUSION

Pharmacovigilance is evolving into a strategic discipline essential for ensuring drug safety and healthcare sustainability. Future advancements will depend on technological innovation, global collaboration, and patient engagement.

Declarations
Funding: None
Conflicts of Interest: The author declares no conflict of interest
Ethical Approval: Not applicable
Data Availability: Not applicable

REFERENCES

1. Aronson, J.K. (2020) 'Artificial intelligence in pharmacovigilance', Drug Safety, 43(6): 495–500.
2. Bate, A. and Evans, S.J.W. (2009) 'Quantitative signal detection using spontaneous ADR reporting', Drug Safety, 32(6): 451–460.
3. Benchoufi, M. and Ravaud, P. (2017) 'Blockchain technology for improving clinical research quality', Trials, 18(1): 335.
4. Edwards, I.R. and Aronson, J.K. (2000) 'Adverse drug reactions: definitions, diagnosis, and management', The Lancet, 356(9237): 1255–1259.
5. EMA (2021) Guidelines on Risk Management Systems. European Medicines Agency.
6. Hazell, L. and Shakir, S.A.W. (2006) 'Under-reporting of adverse drug reactions', Drug Safety, 29(5): 385–396.
7. ICH (2019) Pharmacovigilance Planning Guidelines.
8. IPC (2022) Pharmacovigilance Programme of India Report.
9. Lindquist, M. (2008) 'VigiBase and global drug safety'.
10. McBride, W.G. (1961) 'Thalidomide and congenital abnormalities', The Lancet.
11. Sherman, R.E. et al. (2016) 'Real-world evidence in regulatory decision making', NEJM, 375(23): 2293–2297.
12. WHO (2023) Pharmacovigilance and Drug Safety.